This site uses cookies to provide you with a great user experience. By using BondbloX, you accept our use of cookies.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Teva 3.150% 10/26 (USD)
Teva Pharmaceutical Finance Netherlands III B.V.
Teva Pharmaceutical Industries Limited operates as a pharmaceutical company. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients. Teva Pharmaceutical Industries serves customers worldwide.
to trade this BondbloX
Bondblox Price Information
Last Price
92.500
Yield
7.86%
BondbloX Information
Identifier: BEXISIN
BEXUS88167AAE10
Minimum Trading Size
1,000
BondbloX Features
No voting rights
Accrued Interest
0.638
Coupon / Distribution
Pass through of Underlying Bond coupons & distributions
Listed On
BondbloX Bond Exchange
Underlying Bond Information
Bond Issuer
Teva Pharmaceutical Finance Netherlands III B.V.
ISIN
US88167AAE10
Bond Currency
USD
Country of Risk
ISR
Guarantor
Teva Pharmaceutical Industries Limited
Coupon
3.150%
Coupon Type
Fixed
Industry Type
Pharmaceuticals
Minimum Denomination
2,000
Minimum Increment
1,000
Amount Issued
3,500,000,000
Amount Outstanding
3,377,664,000
Issue Date
Jul 21, 2016
Maturity Date
10/26
Perpetual
N
Redemption Value
100.000
Bond Rating
Moody's:Ba2,S&P:BB-,Fitch:BB
Registration Type
Registered Offering
Seniority
Senior Unsecured
Callable
N
Next Call Date
-
Next Call Price
-
Reference Rate
-
Spread
-
Refix Frequency (years)
-
Coupon / Distribution Information
Coupon Frequency
2
Next Coupon Date
Apr 1, 2025
Day Count Basis
ISMA-30/360
Record Date Rule
1 ICSD Business Day prior to the relevant Interest Payment Date
Underlying Bond Features
Optional Redemption
Teva Finance may redeem the notes of any series, in whole or in part, at any time or from time to time, on at least 20 days’, but not more than 60 days’, prior notice. The notes of each series will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the notes to be redeemed and (2) the sum of the present values of the Remaining Scheduled Payments (as defined under “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate (as defined in “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) plus 25 basis points, in the case of the 2026 notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
Special Mandatory Redemption
If the closing of the Actavis Generics acquisition does not occur on or prior to October 26, 2016, or if the Master Purchase Agreement is terminated at any time prior thereto, the notes will be subject to a special mandatory redemption at a redemption price equal to 101% of their aggregate principal amount, plus accrued and unpaid interest, if any, from the date of initial issuance of the notes up to, but not including, the special redemption date. See “Description of the Notes and the Guarantees—Special Mandatory Redemption.”
Covenants
Limitations on Secured Debt.
If Teva or any of its subsidiaries creates, incurs, assumes or suffers to exist any lien on any of its property (including a subsidiary’s stock or debt) to secure other debt, Teva will secure the notes on the same basis for so long as such other debt is so secured, unless, after giving effect to such lien, the aggregate amount of the secured debt then outstanding (not including debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3) of “—Limitations on Sales and Leasebacks” below would not exceed 10% of Teva’s consolidated net worth. The restrictions do not apply to the following liens:
- liens existing as of the date when Teva Finance first issues notes pursuant to the indenture;
- liens on property created prior to, at the time of or within 120 days after the date of acquisition, completion of construction or completion of improvement of such property to secure all or part of the cost of acquiring, constructing or improving all or any part of such property;
- landlord’s, material men’s, carriers’, workmen’s, repairmen’s or other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being contested in good faith in appropriate proceedings;
- liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva (provided that the lien has not been created or assumed in contemplation of that corporation or other entity becoming a subsidiary of Teva);
- liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries;
- liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws, regulations or statutes; and
- any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not increased and that such lien is not extended to other property.
Limitations on Sales and Leasebacks.
Teva will not, and will not permit any subsidiary to, enter into any sale and leaseback transaction covering any property after the date when Teva Finance first issues notes pursuant to the indenture unless:
1. the sale and leaseback transaction:
- involves a lease for a period, including renewals, of not more than five years;
- occurs within 270 days after the date of acquisition, completion of construction or completion of improvement of such property; or
- is with Teva or one of its subsidiaries; or
2. Teva or any subsidiary, within 270 days after the sale and leaseback transaction shall have occurred, applies or causes to be applied an amount equal to the value of the property so sold and leased back at the time of entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any subsidiary that is not subordinated to the notes and that has a stated maturity of more than twelve months; or
3. Teva or any subsidiary would be entitled pursuant to the exceptions under “—Limitations on Secured Debt” above to create, incur, issue or assume indebtedness secured by a lien in the property without equally and ratably securing the notes.
Certain Other Covenants
The indenture will contain certain other covenants regarding, among other matters, corporate existence and reports to holders of notes.
Related Documents
Final Terms
This document constitutes the Final Terms relating to the issue of BondbloX BEXUS88167AAE10.
Disclaimer
Information regarding the Underlying Bonds is extracted purely on best-efforts basis from the actual program documents currently publicly available to BondEvalue and is not intended to be complete or absolute. No warranty is made as to the completeness or accuracy of such information nor its extraction. Please refer to the actual program documents for complete and accurate information governing the Underlying Bonds.
Teva 3.150% 10/26 (USD)
InstitutionsIndividuals
to trade this BondbloX
Teva Pharmaceutical Finance Netherlands III B.V.
Teva Pharmaceutical Industries Limited operates as a pharmaceutical company. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients. Teva Pharmaceutical Industries serves customers worldwide.
Bondblox Price Information
Last Price
92.500
Yield
7.86%
BondbloX Information
Identifier: BEXISIN
BEXUS88167AAE10
Minimum Trading Size
1,000
BondbloX Features
No voting rights
Accrued Interest
0.638
Coupon / Distribution
Pass through of Underlying Bond coupons & distributions
Listed On
BondbloX Bond Exchange
Settlement Cycle
Instant (Fractional)
Underlying Bond Information
Bond Issuer
Teva Pharmaceutical Finance Netherlands III B.V.
ISIN
US88167AAE10
Bond Currency
USD
Country of Risk
ISR
Guarantor
Teva Pharmaceutical Industries Limited
Coupon
3.150%
Coupon Type
Fixed
Industry Type
Pharmaceuticals
Minimum Denomination
2,000
Minimum Increment
1,000
Amount Issued
3,500,000,000
Amount Outstanding
3,377,664,000
Issue Date
Jul 21, 2016
Maturity Date
10/26
Perpetual
N
Redemption Value
100.000
Bond Rating
Moody's:Ba2
S&P:BB-
Fitch:BB
S&P:BB-
Fitch:BB
Registration Type
Registered Offering
Seniority
Senior Unsecured
Callable
N
Next Call Date
-
Next Call Price
-
Reference Rate
-
Spread
-
Refix Frequency (years)
-
Coupon / Distribution Information
Coupon Frequency
2
Next Coupon Date
Apr 1, 2025
Day Count Basis
ISMA-30/360
Record Date Rule
1 ICSD Business Day prior to the relevant Interest Payment Date
Underlying Bond Features
Optional Redemption
Teva Finance may redeem the notes of any series, in whole or in part, at any time or from time to time, on at least 20 days’, but not more than 60 days’, prior notice. The notes of each series will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the notes to be redeemed and (2) the sum of the present values of the Remaining Scheduled Payments (as defined under “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate (as defined in “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) plus 25 basis points, in the case of the 2026 notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
Special Mandatory Redemption
If the closing of the Actavis Generics acquisition does not occur on or prior to October 26, 2016, or if the Master Purchase Agreement is terminated at any time prior thereto, the notes will be subject to a special mandatory redemption at a redemption price equal to 101% of their aggregate principal amount, plus accrued and unpaid interest, if any, from the date of initial issuance of the notes up to, but not including, the special redemption date. See “Description of the Notes and the Guarantees—Special Mandatory Redemption.”
Covenants
Limitations on Secured Debt.
If Teva or any of its subsidiaries creates, incurs, assumes or suffers to exist any lien on any of its property (including a subsidiary’s stock or debt) to secure other debt, Teva will secure the notes on the same basis for so long as such other debt is so secured, unless, after giving effect to such lien, the aggregate amount of the secured debt then outstanding (not including debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3) of “—Limitations on Sales and Leasebacks” below would not exceed 10% of Teva’s consolidated net worth. The restrictions do not apply to the following liens:
- liens existing as of the date when Teva Finance first issues notes pursuant to the indenture;
- liens on property created prior to, at the time of or within 120 days after the date of acquisition, completion of construction or completion of improvement of such property to secure all or part of the cost of acquiring, constructing or improving all or any part of such property;
- landlord’s, material men’s, carriers’, workmen’s, repairmen’s or other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being contested in good faith in appropriate proceedings;
- liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva (provided that the lien has not been created or assumed in contemplation of that corporation or other entity becoming a subsidiary of Teva);
- liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries;
- liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws, regulations or statutes; and
- any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not increased and that such lien is not extended to other property.
Limitations on Sales and Leasebacks.
Teva will not, and will not permit any subsidiary to, enter into any sale and leaseback transaction covering any property after the date when Teva Finance first issues notes pursuant to the indenture unless:
1. the sale and leaseback transaction:
- involves a lease for a period, including renewals, of not more than five years;
- occurs within 270 days after the date of acquisition, completion of construction or completion of improvement of such property; or
- is with Teva or one of its subsidiaries; or
2. Teva or any subsidiary, within 270 days after the sale and leaseback transaction shall have occurred, applies or causes to be applied an amount equal to the value of the property so sold and leased back at the time of entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any subsidiary that is not subordinated to the notes and that has a stated maturity of more than twelve months; or
3. Teva or any subsidiary would be entitled pursuant to the exceptions under “—Limitations on Secured Debt” above to create, incur, issue or assume indebtedness secured by a lien in the property without equally and ratably securing the notes.
Certain Other Covenants
The indenture will contain certain other covenants regarding, among other matters, corporate existence and reports to holders of notes.
Related Documents
Final Terms
This document constitutes the Final Terms relating to the issue of BondbloX BEXUS88167AAE10.
Disclaimer
Information regarding the Underlying Bonds is extracted purely on best-efforts basis from the actual program documents currently publicly available to BondEvalue and is not intended to be complete or absolute. No warranty is made as to the completeness or accuracy of such information nor its extraction. Please refer to the actual program documents for complete and accurate information governing the Underlying Bonds.
Track the latest bond prices on the BondbloX app
Filter & find the right bond by
using our bond screener
using our bond screener
Track your bond portfolio,
trades, P&L and more
trades, P&L and more
Never miss a new bond issuance again to stay updated on primary markets
BondbloX Pte. Ltd. is regulated by the Monetary Authority of Singapore as a Recognised Market Operator ("RMO") and exempted from Section 49(1) of the Securities and Futures Act (Cap. 289) ("SFA") under Section 49(7) of the SFA.